EUVIMEDEUVIMED entdecken
Leserbrief

Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia

Somedeb Ball iD, Akriti G Jain iD, Najla Al Ali, Luis E Aguirre, Jan Philipp Bewersdorf iD, Andrew Kent, Ameera Rose, Alexander Hayden, Alexa Siddon iD, Jill Lykon, Ellen Madarang, David M Swoboda und 9 weitere

American Journal of Hematology · 2025-10 · 100 (10) · 1920-1923

DOI: 10.1002/ajh.70031 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 07.08.2025. Verfasst von Somedeb Ball und 20 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

NPM1BCL2complete remissioncore binding factoroverall survivalvenetoclax

Autor:innen und Institutionen

  • Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Leukemia Program, Taussig Cancer Institute, Cleveland, Ohio, USA.
  • H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Yale Cancer Center, New Haven, Connecticut, USA.
  • University of Colorado Cancer Center, Aurora, Colorado, USA.

ORCID-Profile: Somedeb Ball, Akriti G Jain, Jan Philipp Bewersdorf, Alexa Siddon, Kendra Sweet, David A Sallman, Jeffrey Lancet, Rami S Komrokji

Zitieren

APA

Ball, S., Jain, A. G., Al Ali, N., Aguirre, L. E., Bewersdorf, J. P., Kent, A., Rose, A., Hayden, A., Siddon, A., Lykon, J., Madarang, E., Swoboda, D. M., Padron, E., Sweet, K., Sallman, D. A., Lancet, J., Carraway, H. E., Watts, J., Zeidan, A., …, & Komrokji, R. S. (2025). Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia. American Journal of Hematology, 100(10), 1920-1923. https://doi.org/10.1002/ajh.70031

Vancouver

Ball S, Jain AG, Al Ali N, Aguirre LE, Bewersdorf JP, Kent A, et al. Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia. American Journal of Hematology. 2025;100(10):1920-1923. doi:10.1002/ajh.70031

BibTeX
@article{Ball2025,
  author = {Ball, Somedeb and Jain, Akriti G and Al Ali, Najla and Aguirre, Luis E and Bewersdorf, Jan Philipp and Kent, Andrew and Rose, Ameera and Hayden, Alexander and Siddon, Alexa and Lykon, Jill and Madarang, Ellen and Swoboda, David M and Padron, Eric and Sweet, Kendra and Sallman, David A and Lancet, Jeffrey and Carraway, Hetty E and Watts, Justin and Zeidan, Amer and Pollyea, Daniel A and Komrokji, Rami S},
  title = {Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {10},
  pages = {1920--1923},
  doi = {10.1002/ajh.70031}
}
Kostenlos starten →